Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib for GVHD Prophylaxis in Haploidentical Stem Cell Transplantation
NCT07570745Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivarmacitinib in graft-versus-host disease (GVHD), sponsored by Shanghai General Hospital. Started May 2026; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07570745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07570745.